MCID: VGN017
MIFTS: 58

Vaginal Cancer

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Vaginal Cancer

MalaCards integrated aliases for Vaginal Cancer:

Name: Vaginal Cancer 12 20 42 15
Malignant Neoplasm of Vagina 12 32
Vaginal Neoplasms 44 70
Vaginal Malignant Epithelial Tumor 58
Malignant Vaginal Neoplasm 70
Malignant Tumor of Vagina 12
Malignant Vaginal Tumor 12
Neoplasm of Vagina 12
Vaginal Carcinoma 58
Vaginal Neoplasia 70
Vaginal Neoplasm 17
Vagina Carcinoma 70
Vagina Neoplasm 12
Vaginal Tumor 12

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:119
ICD9CM 34 184.0
MeSH 44 D014625
NCIt 50 C3437 C7410
SNOMED-CT 67 126921000 188210000
ICD10 32 C52
ICD10 via Orphanet 33 C52
UMLS via Orphanet 71 C0262659
Orphanet 58 ORPHA180247
UMLS 70 C0042237 C0042258 C0262659 more

Summaries for Vaginal Cancer

MedlinePlus : 42 Vaginal cancer is a rare type of cancer. It is more common in women 60 and older. You are also more likely to get it if you have had a human papillomavirus (HPV) infection or if your mother took diethylstilbestrol (DES) when she was pregnant. Doctors prescribed DES in the 1950's to prevent miscarriages. You are also at higher risk if you have had abnormal cells in the vagina, cervix, or uterus. It often doesn't have early symptoms. However, see your doctor if you notice Bleeding that is not your period A vaginal lump Pelvic pain A Pap test can find abnormal cells that may be cancer. Vaginal cancer can often be cured in its early stages. Treatment might include surgery, radiation therapy, and chemotherapy. NIH: National Cancer Institute

MalaCards based summary : Vaginal Cancer, also known as malignant neoplasm of vagina, is related to human papillomavirus infectious disease and vaginal endometrial stromal tumor, and has symptoms including pelvic pain and vaginal pruritus. An important gene associated with Vaginal Cancer is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways are Gastric cancer and Human T-cell leukemia virus 1 infection. The drugs Granisetron and Ondansetron have been mentioned in the context of this disorder. Affiliated tissues include vagina, cervix and uterus, and related phenotypes are cellular and homeostasis/metabolism

Disease Ontology : 12 A female reproductive system cancer that is located in the vagina.

Wikipedia : 73 Vaginal cancer is a malignant tumor that forms in the tissues of the vagina. Primary tumors are most... more...

Related Diseases for Vaginal Cancer

Diseases related to Vaginal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 417)
# Related Disease Score Top Affiliating Genes
1 human papillomavirus infectious disease 32.0 TP53 CDKN2A
2 vaginal endometrial stromal tumor 31.8 MME CALD1
3 vaginal disease 31.7 TP53 GP5 CD4
4 vagina sarcoma 31.2 PGR MME CALD1
5 vulvar intraepithelial neoplasia 30.5 TP53 CDKN2A
6 cervix uteri carcinoma in situ 30.5 TP53 INSM1 GP5 CDKN2A
7 vulva cancer 30.2 TP53 KRT7 GP5 CDKN2A
8 squamous cell papilloma 30.1 TP53 GP5 CDKN2A
9 keratinizing squamous cell carcinoma 30.0 TP53 KRT7 CDKN2A
10 suppressor of tumorigenicity 3 30.0 UBE3A TP53 CDKN2A
11 adenosquamous carcinoma 30.0 TP53 KRT7 CDKN2A
12 adenocarcinoma in situ 30.0 KRT7 INSM1 CDKN2A
13 adult t-cell leukemia 29.8 TP53 CDKN2A CD4
14 vaginitis 29.7 ESR2 ESR1 CD4
15 leiomyosarcoma 29.6 TP53 PGR ESR1 CDKN2A
16 in situ carcinoma 29.6 TP53 PRDX2 PGR ESR1 CDKN2A
17 rhabdomyosarcoma 29.6 TP53 MME KRT7 ESR1 CDKN2A
18 mammary paget's disease 29.5 PGR KRT7 ESR1
19 vulvar disease 29.4 TP53 KRT7 GP5 CDKN2A CD4
20 anus cancer 29.4 UBE3A TP53 KRT7 GP5 CDKN2A CD4
21 papilloma 29.3 UBE3A TP53 KRT7 CDKN2A CD4
22 pelvic organ prolapse 29.1 TP53 PGR ESR2 ESR1
23 endometrial hyperplasia 29.1 TP53 PGR ESR2 ESR1
24 myoma 29.0 TP53 PGR MME ESR1 CALD1
25 endometrial cancer 28.6 TP53 PGR MME KRT7 ESR2 ESR1
26 vaginal carcinosarcoma 11.0
27 vaginal glandular tumor 11.0
28 vaginal squamous tumor 11.0
29 vaginal yolk sac tumor 11.0
30 diethylstilbestrol syndrome 11.0
31 early invasive cervical adenocarcinoma 10.4 INSM1 CDKN2A
32 esophagus verrucous carcinoma 10.4 TP53 CDKN2A
33 spitz nevus 10.4 TP53 CDKN2A
34 cervical basaloid squamous cell carcinoma 10.4 KRT7 CDKN2A
35 inverted transitional papilloma 10.4 KRT7 CDKN2A
36 adult malignant schwannoma 10.4 TP53 CDKN2A
37 pancreatic foamy gland adenocarcinoma 10.4 TP53 KRT7
38 anal canal paget's disease 10.4 KRT7 CDKN2A
39 cervical adenoid cystic carcinoma 10.4 KRT7 CDKN2A
40 supraglottis cancer 10.4 TP53 CDKN2A
41 breast hemangioma 10.4 TP53 KRT7
42 mucinous adenofibroma 10.4 KRT7 ESR1
43 vaginal tubulovillous adenoma 10.3 KRT7 CDKN2A
44 necrotizing sialometaplasia 10.3 TP53 KRT7
45 benign breast adenomyoepithelioma 10.3 KRT7 ESR1
46 intratubular embryonal carcinoma 10.3 TP53 KRT7
47 papillary transitional carcinoma 10.3 TP53 KRT7
48 microinvasive cervical squamous cell carcinoma 10.3 KRT7 INSM1
49 large cell acanthoma 10.3 TP53 KRT7
50 gallbladder adenoma 10.3 KRT7 CDKN2A

Comorbidity relations with Vaginal Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Cervical Cancer
Deficiency Anemia Vulva Cancer

Graphical network of the top 20 diseases related to Vaginal Cancer:



Diseases related to Vaginal Cancer

Symptoms & Phenotypes for Vaginal Cancer

UMLS symptoms related to Vaginal Cancer:


pelvic pain; vaginal pruritus

MGI Mouse Phenotypes related to Vaginal Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 CD4 CDKN2A ESR1 ESR2 INSM1 KRT7
2 homeostasis/metabolism MP:0005376 10 CD4 CDKN2A ESR1 ESR2 GP5 HLA-G
3 integument MP:0010771 9.61 CD4 CDKN2A ESR1 ESR2 MME OGN
4 no phenotypic analysis MP:0003012 9.23 CD4 CDKN2A ESR1 ESR2 INSM1 PGR

Drugs & Therapeutics for Vaginal Cancer

Drugs for Vaginal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
2
Ondansetron Approved Phase 3 99614-02-5 4595
3
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
4
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 5881
5 DHEA (Dehydroepiandrosterone) Phase 3
6 Gastrointestinal Agents Phase 3
7 Antiemetics Phase 3
8 Dermatologic Agents Phase 3
9 Antipsychotic Agents Phase 3
10 Anti-Anxiety Agents Phase 3
11 Emetics Phase 3
12 Antineoplastic Agents, Hormonal Phase 3
13 Immunologic Factors Phase 3
14 Vaccines Phase 3
15
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
16
Fondaparinux Approved, Investigational Phase 2 104993-28-4
17
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
18
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
19
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
20
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
21
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
22
Mycophenolic acid Approved Phase 2 24280-93-1 446541
23
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
24
Bevacizumab Approved, Investigational Phase 2 216974-75-3
25
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
26
Durvalumab Approved, Investigational Phase 2 1428935-60-7
27
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
28
Bupropion Approved Phase 2 34841-39-9, 34911-55-2 444
29
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
30
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
31 Serine Proteinase Inhibitors Phase 2
32 Anticoagulants Phase 2
33 Fibrinolytic Agents Phase 2
34 Antithrombin III Phase 2
35
protease inhibitors Phase 2
36 Factor Xa Inhibitors Phase 2
37 PENTA Phase 2
38 HIV Protease Inhibitors Phase 2
39 Antithrombins Phase 2
40 Antibiotics, Antitubercular Phase 2
41 Anti-Infective Agents Phase 1, Phase 2
42 Immunosuppressive Agents Phase 1, Phase 2
43 Antifungal Agents Phase 2
44 Anti-Bacterial Agents Phase 2
45 Antirheumatic Agents Phase 1, Phase 2
46 Alkylating Agents Phase 1, Phase 2
47 Anti-Retroviral Agents Phase 1, Phase 2
48 Antiviral Agents Phase 1, Phase 2
49 Anti-HIV Agents Phase 1, Phase 2
50 Fluorodeoxyglucose F18 Phase 2

Interventional clinical trials:

(show top 50) (show all 96)
# Name Status NCT ID Phase Drugs
1 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
2 Evaluation of Safety and Immunogenicity of GARDASIL™ in Healthy Females Between 9 and 26 Years of Age in SubSaharan Africa Completed NCT01245764 Phase 3
3 Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial Completed NCT01376349 Phase 3 prasterone
4 Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation Completed NCT01536392 Phase 3 Granisetron;Ondansetron
5 Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy Completed NCT00033605 Phase 3 octreotide acetate
6 A Randomized Phase III Trial for Evaluation of Usefulness of Pelvic Drains After Radical Hysterectomy and Node Dissection (RHND) Completed NCT00003267 Phase 3
7 An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds) Completed NCT03158220 Phase 3
8 A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
9 A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL™ Completed NCT01047345 Phase 3
10 A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women Completed NCT00543543 Phase 3
11 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
12 A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Recruiting NCT02466971 Phase 3 Cisplatin;Triapine
13 A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) and 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years Recruiting NCT04425291 Phase 3
14 A Multicenter,Randomized,Blind and Positive-Controlled Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years Recruiting NCT04422366 Phase 3
15 A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds) Active, not recruiting NCT00943722 Phase 3
16 Systematic Nutritional Care in Patients Receiving First-line Chemotherapy for Metastatic Gynecologic Cancer in a Phase II Study Unknown status NCT00905658 Phase 2
17 Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial Completed NCT00381888 Phase 2 fondaparinux sodium
18 A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
19 A Phase 2 Study of Triapine® (NSC #663249) and Cisplatin in Combination With Pelvic Radiation for Treatment of Stage IB2-IVa Cervical Cancer or Stage II-IV Vaginal Cancer Completed NCT00941070 Phase 2 triapine;cisplatin
20 Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy Completed NCT00005941 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
21 EVALUATION OF PACLITAXEL (TAXOL) IN PERSISTENT OR RECURRENT NON-SQUAMOUS CELL CARCINOMA OF THE CERVIX AND VAGINA Completed NCT00002562 Phase 2 paclitaxel
22 Psychosexual Intervention for Gynecologic and Breast Cancer Patients Completed NCT01764802 Phase 2
23 Effectiveness of an Individualized Symptom Education Program (ISEP) on the Symptom Distress of Women Receiving Radiation for Gynecological Cancer. Completed NCT00275353 Phase 2
24 A Pilot Study of Conformal Intensity Modulated Radiation Therapy (IMRT) for Gynaecological Cancer Patients Not Suitable for Intracavitary Brachytherapy Boost (GY03.2) Completed NCT00188578 Phase 1, Phase 2
25 A Prospective Evaluation of a Palliative Radio-Surgical Approach for the Treatment of Gynecologic Malignancies Completed NCT01079832 Phase 2
26 A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered Concomitantly With GARDASIL to 16- to 26- Year-Old Women Completed NCT00551187 Phase 2
27 A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
28 A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO) Completed NCT01399658 Phase 2
29 A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women Completed NCT00520598 Phase 2 Comparator: V505 formulation 2;Comparator: V505 formulation 2
30 A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers Completed NCT00545792 Phase 2 Avastin
31 The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
32 A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers Recruiting NCT03439085 Phase 2
33 Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer Active, not recruiting NCT03180294 Phase 2 Bupropion Hydrochloride
34 A Phase II Study of VELCADE TM(PS-341) and Irinotecan in the Treatment of Progressive, Recurrent or Metastatic Cervical, Vulvar, or Vaginal Cancer Terminated NCT00106262 Phase 2 Velcade (bortezomib);Irinotecan
35 A Phase I/II Feasibility/Efficacy Study of HIFU in Otherwise Untreatable Pelvic Rectal Cancer Withdrawn NCT01097239 Phase 1, Phase 2
36 A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Withdrawn NCT03220009 Phase 2
37 Pilot Study on Concurrent Cisplatin-based Chemotherapy Combined With Vaccination Therapy With the P16_37-63 Peptide in Patients With HPV- and p16INK4a-positive Cancer Completed NCT02526316 Phase 1
38 A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies Completed NCT00523432 Phase 1 Topotecan;CCI-779 (temsirolimus)
39 Phase I Study of Intravenous Triapine® (IND #68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies. Completed NCT00335998 Phase 1 triapine;cisplatin
40 Phase I Study of Metronomic Daily Dosing of Docetaxel in Women With Progressive or Recurrent Gynecologic Cancer Completed NCT00287885 Phase 1 docetaxel
41 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
42 Phase I Study of Concomitant Chemoradiotherapy With Vinorelbine and Paclitaxel in Patients With Advanced Pelvic Malignancies Completed NCT00002949 Phase 1 paclitaxel;vinorelbine tartrate
43 A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Primary Immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years Completed NCT03676101 Phase 1
44 A Randomized, Double-Blind, Multicenter, Biphasic, Controlled With GARDASIL™ Dose-Escalation Study of Octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and ISCOMATRIX™ (IMX) Completed NCT00851643 Phase 1
45 A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
46 A Phase I Study of Weekly Oral Topotecan in Gynecologic Malignancies Completed NCT00842452 Phase 1 topotecan hydrochloride
47 Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer Recruiting NCT02595879 Phase 1 Cisplatin;Triapine
48 MRI Guided Brachytherapy for HPV-Associated Cervical and Vaginal Malignancies Recruiting NCT03634267 Phase 1
49 Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers Recruiting NCT03968406 Phase 1 Talazoparib
50 Phase I Multi-Center Study of Hypofractionated Radiotherapy in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer Recruiting NCT03452332 Phase 1

Search NIH Clinical Center for Vaginal Cancer

Cochrane evidence based reviews: vaginal neoplasms

Genetic Tests for Vaginal Cancer

Anatomical Context for Vaginal Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Vaginal Cancer:

19
Vagina

MalaCards organs/tissues related to Vaginal Cancer:

40
Cervix, Uterus, Bone, Lymph Node, Breast, Spleen, Skin

Publications for Vaginal Cancer

Articles related to Vaginal Cancer:

(show top 50) (show all 608)
# Title Authors PMID Year
1
Survival benefit of vaginectomy compared to local tumor excision in women with FIGO stage I and II primary vaginal carcinoma: a SEER study. 61 42
32780160 2020
2
Lower Genital Tract Melanomas: Staging, Predictors of Outcome, and New Therapeutic Options. 42
33517307 2021
3
The role of sentinel lymph node mapping in lower genital tract melanoma. 42
32744452 2020
4
Incidence of human papillomavirus-related anogenital precancer and cancer in women with diabetes: A nationwide registry-based cohort study. 61
33129233 2021
5
Clinical presentation, treatment, and outcomes associated with vaginal intraepithelial neoplasia: A retrospective study of 118 patients. 61
33754436 2021
6
Uterine transposition for gynecological cancers. 61
33649011 2021
7
Image-Guided Adaptive Brachytherapy (IGABT) for Primary Vaginal Cancer: Results of the International Multicenter RetroEMBRAVE Cohort Study. 61
33806733 2021
8
New frontiers of developmental endocrinology opened by researchers connecting irreversible effects of sex hormones on developing organs. 61
33189416 2021
9
Gynecologic Malignancies in Children and Adolescents: How Common is the Uncommon? 61
33673108 2021
10
Primary vaginal cancer associated with HPV 68: A case report of an unusual presentation. 61
32862465 2021
11
Porphyria cutanea tarda exacerbation as a paraneoplastic syndrome in vaginal cancer resolved with chemoradiation. 61
33426257 2021
12
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2017 and annual treatment report for 2012. 61
33631867 2021
13
The impact of brachytherapy boost and radiotherapy treatment duration on survival in patients with vaginal cancer treated with definitive chemoradiation. 61
33008762 2021
14
Assessment of an onco-sexology support and follow-up program in cervical or vaginal cancer patients undergoing brachytherapy. 61
33411047 2021
15
3D image-guided interstitial brachytherapy for primary vaginal cancer: A multi-institutional experience. 61
33162177 2021
16
A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. 61
32338316 2021
17
IRIDIUM-192 RADIOTHERAPY BENEFITS IN THE MANAGEMENT OF GYNECOLOGICAL TUMORS. 61
33361862 2020
18
Primary Vaginal Carcinoma Arising on Cystocele Mimicking Vulvar Cancer. 61
32446632 2020
19
Diagnostic benefit of cytological and histopathological examinations for recurrent vaginal cancer metastasizing to the duodenum: A case report. 61
33363849 2020
20
Occult vaginal cancer recurrence after hysterectomy: a case report and literature review. 61
33275476 2020
21
Gynecological cancers and the global COVID-19 pandemic 61
33274617 2020
22
Management and outcomes of primary vaginal Cancer. 61
32972784 2020
23
A custom-made brachytherapy applicator for recurrent endometrial and vaginal cancer: A dental technique for prosthesis fabrication. 61
33162114 2020
24
Geographic and temporal variations in the incidence of vulvar and vaginal cancers. 61
32410226 2020
25
Clinical Characteristics and Long-Term Follow-up of Patients Treated for High-Grade Vaginal Intraepithelial Neoplasia: Results From a 20-Year Survey in Italy. 61
32881786 2020
26
Application of 5-aminolevulinic acid photodynamic therapy for vaginal intraepithelial neoplasia, a report of six cases. 61
32473400 2020
27
Outcomes by Race Among Women Referred to an Academic Colposcopy Clinic with a Patient Navigation Program. 61
32960144 2020
28
CD4 Trajectory Models and Onset of Non-AIDS-Defining Anal Genital Warts, Precancer, and Cancer in People Living With HIV Infection-1. 61
32530855 2020
29
Positive sentinel lymph node in a patient with clinical stage I vaginal cancer. 61
32596436 2020
30
Laparoendoscopic single-site inguinal lymphadenectomy in gynecology: preliminary experience at a single institution. 61
32556531 2020
31
Surgical treatment of complete uterovaginal prolapse and concomitant vaginal cancer: a video case report. 61
32125490 2020
32
Palliative treatment with electrochemotherapy in recurrent or metastatic vaginal cancer. 61
32474450 2020
33
Effective combination of lymphatico-venous anastomosis and negative pressure wound therapy for lymphocyst: A Case Study. 61
32464690 2020
34
Pelvic radiation therapy with volumetric modulated arc therapy and intensity-modulated radiotherapy after renal transplant: A report of 3 cases. 61
32494227 2020
35
Clinical outcomes of transarterial chemotherapy and embolization for vaginal cancer. 61
32144875 2020
36
Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. 61
32125711 2020
37
Gynecologic cancer in pregnancy. 61
32268951 2020
38
[Preliminary study of the clinical value of colposcopy in diagnosing vagina invasion in cervical cancer]. 61
32464720 2020
39
Locally-advanced vaginal cancer with complete utero-vaginal prolapse. 61
32139436 2020
40
An application of ERBB2 receptor inhibitors in a rare case of S310F somatic ERBB2 mutation of primary signet-ring cell adenocarcinoma of vagina: A case report and review literature of S310F somatic ERBB2 mutation in breast and gynecologic cancers. 61
32405522 2020
41
Clinical outcomes of vaginectomy and laser ablation for the treatment of post-hysterectomy women with vaginal high-grade squamous intraepithelial lesions: A retrospective study. 61
32199295 2020
42
The costs of treating vaginal and vulval cancer in England (2009-2015). 61
32252711 2020
43
Recommendations from gynaecological (GYN) GEC-ESTRO working group - ACROP: Target concept for image guided adaptive brachytherapy in primary vaginal cancer. 61
31874348 2020
44
Using a pessary during radiotherapy in reducible pelvic organ prolapse and vaginal cancer: a case report and review of the literature. 61
32395142 2020
45
The interplay of HIV and human papillomavirus-related cancers in sub-Saharan Africa: scoping review. 61
32321580 2020
46
Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer. 61
32135119 2020
47
The risk of vaginal cancer is associated with a history of cervical neoplasia. 61
31863542 2020
48
Risk of vaginal cancer among hysterectomised women with cervical intraepithelial neoplasia: a population-based national cohort study. 61
31769577 2020
49
Hyaluronic acid gel injection in rectovaginal septum reduced incidence of rectal bleeding in brachytherapy for gynecological malignancies. 61
31879238 2020
50
Vulvar and vaginal neoplasia in women with inflammatory bowel disease. 61
31718933 2020

Variations for Vaginal Cancer

Cosmic variations for Vaginal Cancer:

9 (show top 50) (show all 940)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM139294266 STAT3 vagina,NS,carcinoma,squamous cell carcinoma c.1110-2A>G p.? 17:42329778-42329778 24
2 COSM103491068 STAT3 vagina,NS,carcinoma,squamous cell carcinoma c.1110-2A>G p.? 17:42329778-42329778 24
3 COSM99883612 STAT3 vagina,NS,carcinoma,squamous cell carcinoma c.816-2A>G p.? 17:42329778-42329778 24
4 COSM88453086 STAT3 vagina,NS,carcinoma,squamous cell carcinoma c.1110-2A>G p.? 17:42329778-42329778 24
5 COSM140296740 STAT3 vagina,NS,carcinoma,squamous cell carcinoma c.1110-2A>G p.? 17:42329778-42329778 24
6 COSM97074901 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3409G>A p.E1137K 20:42106824-42106824 24
7 COSM142601992 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.2256G>A p.E753K 20:42106824-42106824 24
8 COSM144161135 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.2206G>A p.E736K 20:42106824-42106824 24
9 COSM96630253 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3382G>A p.E1128K 20:42106824-42106824 24
10 COSM96848041 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3349G>A p.E1117K 20:42106824-42106824 24
11 COSM97172725 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3322G>A p.E1108K 20:42106824-42106824 24
12 COSM96960471 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3418G>A p.E1140K 20:42106824-42106824 24
13 COSM93285904 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3379G>A p.E1127K 20:42106824-42106824 24
14 COSM96733209 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3352G>A p.E1118K 20:42106824-42106824 24
15 COSM92613846 NSD1 vagina,NS,carcinoma,squamous cell carcinoma c.4910G>T p.G1637V 5:177280659-177280659 24
16 COSM109089776 NSD1 vagina,NS,carcinoma,squamous cell carcinoma c.5717G>T p.G1906V 5:177280659-177280659 24
17 COSM92689842 NSD1 vagina,NS,carcinoma,squamous cell carcinoma c.4910G>T p.G1637V 5:177280659-177280659 24
18 COSM86305871 NFKBIA vagina,NS,carcinoma,squamous cell carcinoma c.127G>C p.E43Q 14:35404518-35404518 24
19 COSM133974130 NFKBIA vagina,NS,carcinoma,squamous cell carcinoma c.127G>C p.E43Q 14:35404518-35404518 24
20 COSM102100255 EIF1AX vagina,NS,carcinoma,squamous cell carcinoma c.331G>T p.E111* 23:20130530-20130530 24
21 COSM102100262 EIF1AX vagina,NS,carcinoma,squamous cell carcinoma c.17-2734G>C p.? 23:20138575-20138575 24
22 COSM102126713 EIF1AX vagina,NS,carcinoma,squamous cell carcinoma c.415G>T p.E139* 23:20130530-20130530 24
23 COSM102126718 EIF1AX vagina,NS,carcinoma,squamous cell carcinoma c.64G>C p.E22Q 23:20138575-20138575 24
24 COSM88614470 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
25 COSM101446479 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
26 COSM94832378 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
27 COSM101464008 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
28 COSM101457530 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
29 COSM101451548 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
30 COSM101460995 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
31 COSM92091529 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
32 COSM97571573 ATRX vagina,NS,carcinoma,squamous cell carcinoma c.4498G>A p.E1500K 23:77652173-77652173 24
33 COSM100346016 ATRX vagina,NS,carcinoma,squamous cell carcinoma c.4384G>A p.E1462K 23:77652173-77652173 24
34 COSM123189243 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.270G>A p.L90= 8:116848969-116848969 3
35 COSM127848324 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.127G>A p.E43K 8:116848969-116848969 3
36 COSM123189233 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.249G>A p.L83= 8:116848948-116848948 3
37 COSM127848316 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.106G>A p.E36K 8:116848948-116848948 3
38 COSM101184918 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4630C>G p.L1544V 16:2086857-2086857 3
39 COSM90408532 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4906C>G p.L1636V 16:2086857-2086857 3
40 COSM149806850 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4843C>G p.L1615V 16:2086857-2086857 3
41 COSM87033167 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4975C>G p.L1659V 16:2086857-2086857 3
42 COSM151515645 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4900C>G p.L1634V 16:2086857-2086857 3
43 COSM150318236 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4774C>G p.L1592V 16:2086857-2086857 3
44 COSM102623419 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4774C>G p.L1592V 16:2086857-2086857 3
45 COSM151373080 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4969C>G p.L1657V 16:2086857-2086857 3
46 COSM150359241 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4771C>G p.L1591V 16:2086857-2086857 3
47 COSM151750121 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4846C>G p.L1616V 16:2086857-2086857 3
48 COSM110108009 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4666C>G p.L1556V 16:2086857-2086857 3
49 COSM148986154 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4777C>G p.L1593V 16:2086857-2086857 3
50 COSM136621744 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4807C>G p.L1603V 16:2086857-2086857 3

Expression for Vaginal Cancer

Search GEO for disease gene expression data for Vaginal Cancer.

Pathways for Vaginal Cancer

Pathways related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.22 TP53 PGR ESR2 ESR1 CDKN2A
2 11.9 TP53 HLA-G CDKN2A CD4
3 11.57 UBE3A TP53 HLA-G CDKN2A
4 11.54 MME GP5 CD4
5
Show member pathways
11.45 PGR ESR2 ESR1
6 9.23 ESR2 ESR1

GO Terms for Vaginal Cancer

Biological processes related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.73 TP53 PGR ESR1 EIF4A3
2 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.4 TP53 ESR1
3 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.37 TP53 ESR1
4 positive regulation of cell cycle arrest GO:0071158 9.33 TP53 INSM1 CDKN2A
5 cellular response to brain-derived neurotrophic factor stimulus GO:1990416 9.32 UBE3A EIF4A3
6 progesterone receptor signaling pathway GO:0050847 9.26 UBE3A PGR
7 replicative senescence GO:0090399 9.13 TP53 MME CDKN2A
8 intracellular steroid hormone receptor signaling pathway GO:0030518 8.8 PGR ESR2 ESR1

Molecular functions related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.88 TP53 PGR MME ESR2 ESR1 CD4
2 enzyme binding GO:0019899 9.65 TP53 PGR ESR2 ESR1 CD4
3 nuclear receptor activity GO:0004879 9.54 PGR ESR2 ESR1
4 MDM2/MDM4 family protein binding GO:0097371 9.43 TP53 CDKN2A
5 estrogen receptor activity GO:0030284 9.32 ESR2 ESR1
6 estrogen response element binding GO:0034056 9.16 ESR2 ESR1
7 steroid binding GO:0005496 9.13 PGR ESR2 ESR1
8 steroid hormone receptor activity GO:0003707 8.8 PGR ESR2 ESR1

Sources for Vaginal Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....